On February 22, 2017, Ministry of Science and Technology major projects office in the Ministry of Science and Technology press hall held a press conference on Major Science &Technology Project for 'Significant New Drugs Creation', the meeting was presided over by Chuanhong Chen, the officer of the Ministry of Science and Technology major projects. Conglin Zuo, JOINN CEO, was invited to attend the press conference. The conference focused on the construction of the technology platform for non-clinical safety evaluation of drugs in China. Dr. Guowei Sang said at the conference that a series of major breakthroughs had been made in the construction of non-clinical safety evaluation platform for drugs in China: The evaluation work of the platform is in line with international standards, the core key technologies reach the international advanced level, and the talent team and management level are constantly improved. The non-clinical drug safety evaluation platform in China strongly supports the research and development of new drugs in China, and ensures the safety of drug use for the public.

As a service platform, JOINN undertook the subject project of "Construction of International Innovative Drug Safety Evaluation Technology Platform" during the "Twelfth Five-year Plan", and achieved remarkable results.

1. Strengthen The Internal Service abilities

JOINN has passed the CFDA GLP inspection and AAALAC certification successively, and successfully passed the US FDA GLP inspection in July 2009, September 2013 and August 2016 respectively; successfully obtained the GLP certification of OECD in Poland and MFDS in Korea in August 2015 and October 2016 successively. The level of GLP management and technology research is gradually in line with international standards, and GLP qualification has been qualitatively changed.

With the support of the project, the total scale of JOINN's facilities in Beijing and Suzhou reaches 73000m2, which ranks first in China and ranks among the largest CRO in the world. The two places have a professional and technical team of nearly 600 people, and more than 30 international talents have been introduced, including high-level talents introduced from FDA of the United States, 5 new drug evaluation experts and 2 GLP inspection experts. The talent team and management level have been significantly improved.

2. Major breakthroughs in key technologies

During the 12th Five-Year Plan period, JOINN has built a comprehensive ophthalmic drug delivery technology and experimental capability, which greatly supports the ophthalmic toxicity observation of systematic drug delivery and preclinical evaluation of ophthalmic drugs. In addition, JOINN also established the inhalation toxicity evaluation system for rats and beagle dogs, which passed the complex equipment verification, and carried out the toxicity test for inhalation administration. The lung function detection system of awake animals was established, which provided support for the evaluation of respiratory function and the development of respiratory drugs. The carcinogenic tests of conventional and transgenic animals were established in accordance with international standards. The ability to evaluate the safety of juvenile rats, dogs and non-human primates was established. Key technical capabilities such as a variety of bioanalytical methods with strong specificity and high sensitivity have been established, and major breakthroughs in core key technologies have been achieved, providing an important technical guarantee for the safety evaluation of new drugs.

3.Significant improvement in technical service capability

As the only private company to be invited to the conference, JOINN felt honored and felt the great responsibility at the same time. As the "13th Five-Year Plan" is coming, JOINN will continue to work hard and develop continuously on the basis of the existing good foundation. In terms of international development, JOINN will strive to obtain a more comprehensive international GLP certification and recognition, constantly enhance international competitiveness, and make contributions to ensuring that China's innovative drugs enter the first tier of the international team. In the construction of innovation service ability, we will also according to the need of drug innovation, constantly develop and establish a new technology, new method and key construction of respiratory function evaluation ability, assessment of the central nervous system function, isotope and molecular imaging technology, automation, and the application of information technology, to promote drug evaluation ability again on the steps; Taking advantage of the advantages of the enterprise, the company will constantly improve its comprehensive service capability and boost the pharmaceutical innovation and industry development in China.